Last reviewed · How we verify
Gynuity Health Projects — Portfolio Competitive Intelligence Brief
4 marketed
0 filed
0 Phase 3
0 Phase 2
1 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Buccal misoprostol | Buccal misoprostol | marketed | ||||
| Mifepristone + Misoprostol | Mifepristone + Misoprostol | marketed | Progesterone receptor antagonist + prostaglandin analog combination | Progesterone receptor (PR); prostaglandin E1 receptor (EP receptor) | Reproductive Health / Gynecology | |
| Mifepristone and misoprostol | Mifepristone and misoprostol | marketed | Progesterone antagonist + prostaglandin analog combination | Progesterone receptor (mifepristone); prostaglandin E1 receptor (misoprostol) | Reproductive Health / Obstetrics | |
| Placebo mifepristone | Placebo mifepristone | marketed |
Therapeutic area mix
- Other · 1
- Reproductive Health / Gynecology · 1
- Reproductive Health / Obstetrics · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Hadassah Medical Organization · 1 shared drug class
- Planned Parenthood League of Massachusetts · 1 shared drug class
- Reproductive Health Training Center of the Republic of Moldova · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Gynuity Health Projects:
- Gynuity Health Projects pipeline updates — RSS
- Gynuity Health Projects pipeline updates — Atom
- Gynuity Health Projects pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Gynuity Health Projects — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gynuity-health-projects. Accessed 2026-06-10.